How Does Smoking Impact High Blood Pressure Risk?
Smoking causes a temporary rise in blood pressure, but does that impact hypertension risk over the course of a lifetime?
Tag: PAH and pulmonary hypertension
All
Latest
All
Latest
Pulmonary Hypertension May Raise Kidney Failure Risk For Certain Patients
Patients who have chronic kidney disease and pulmonary hypertension are at a greater risk for a variety of adverse outcomes, according to new research.
All
Latest
Aftermath of Pulmonary Endarterectomy in Chronic Thromboembolic Pulmonary Hypertension
Exercise intolerance is common in patients with chronic thromboembolic pulmonary hypertension after undergoing pulmonary endarterectomy, a new study finds.
Pulmonary Hypertension Implant Gets FDA Breakthrough Tag
The implantable Aria CV Pulmonary Hypertension System has received a breakthrough device designation from the FDA, according to the manufacturer Aria CV.
Read More
Pulmonary Hypertension Treatment Trial Shows Positive Results
Acceleron Pharma’s investigational treatment for pulmonary arterial hypertension showed positive outcomes in a mid-stage trial, the company announced on Monday.
Read More
Dofetilide/Tikosyn May Be Effective for Pulmonary Arterial Hypertension
New research found that the cardiac arrhythmia treatment Tikosyn (dofetilide) may be used for treatment of pulmonary arterial hypertension (PAH).
Read More
Better Risk Calculator for Pulmonary Arterial Hypertension
For patients with pulmonary arterial hypertension, updating the REVEAL risk calculator to include all-cause hospitalization was a better discriminator of risk than existing risk stratification tools.
Read More
Pulmonary Arterial Hypertension Treatment With Macitentan Is Safe and Effective for Patients With Systemic Sclerosis
Patients with pulmonary arterial hypertension (PAH) associated with systemic sclerosis (SSc) who...
Read More
Pulmonary Arterial Hypertension Patients Benefit from Macitentan + Tadalafil Combo
Patients newly diagnosed with pulmonary arterial hypertension treated with macitentan and tadalafil combination therapy showed hemodynamic progress, as well as improvements in function and risk profile.
Read More
No Benefit for Idiopathic Interstitial Pneumonia-associated PH Patients Treated with Adempas
For patients with idiopathic interstitial pneumonia-associated pulmonary hypertension, treatment with riociguat (Adempas) was not beneficial compared to placebo, and increased adverse events.
Read MoreSelexipag Functionally Improves Pulmonary Hypertension Patients with COPD
Selexipag could improve functional status associated with chronic obstructive pulmonary disease (COPD)among patients with pulmonary hypertension (PH), according to findings from a new study.In trial data presented at...
Read MoreNew Drug Target Discovered for the Lung Disease PAH
Scientists have identified a molecular pathway that contributes to the development of pulmonary arterial hypertension (PAH), a severe, often fatal condition that has no cure. The discovery, published Sept. 12, 2019,...
Read More
Pulmonary Arterial Hypertension Device Receives FDA Breakthrough Designation
SoniVie has been granted breakthrough device designation from the US FDA for their device to treat patients with pulmonary arterial hypertension (PAH).
Read More
Tumor-suppressing Protein May Be Novel Target in PAH Therapy
In addition to suppressing tumors, the protein tuberous sclerosis complex 2 (TSC2) may play a role in preventing or treating pulmonary arterial hypertension (PAH).
Read More
Selexipag Improved Clinical Outcomes in Pulmonary Arterial Hypertension
Treatment with selexipag versus placebo improved clinical outcomes in patients with pulmonary arterial hypertension (PAH) regardless of the time from diagnosis to drug initiation.
Read More